Fundraising Fox
Kumquat Biosciences
San Diego, US · Founded 2018 · Delaware corporation · 3 known investors
Find your way into Kumquat Biosciences
Sign up to see every warm intro you have to Kumquat Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Kumquat Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Kumquat Biosciences is a biotech company developing small-molecule cancer therapeutics, combining drug discovery and clinical expertise to advance new oncology treatments. It focuses on translating research into therapies for cancer patients.
Founders & leadership
Kumquat Biosciences was founded in 2018 by Yi Liu and Yi Liu, Ph.D..
YL
Yi Liu, Ph.D.CEO
LY
Lynn YangNamed on SEC filing
Board
CG
Investors · 3
OrbiMedlisted by OrbiMedNew York · $1M – $75M
How we know: OrbiMed's portfolio page · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$135.9M disclosed across 3 rounds · 2019–2021
▶$30MraisedAug 2021 · 3 investors · BiotechnologyRule 506(b)
▶$30MraisedAug 2021 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Pingda RenExecutive Officer
- Scott PlatshonDirector
- Lynn YangDirector
- Carl GordonDirector
- Yi LiuExecutive Officer, Director
- Offering amount
- $30M
- Amount sold
- $30M
- Minimum investment
- $12
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$50MraisedFeb 2021 · 8 investors · BiotechnologyRule 506(b)
▶$50MraisedFeb 2021 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Yi LiuExecutive Officer, Director
- Lynn YangDirector
- Carl GordonDirector
- Scott PlatshonDirector
- Pingda RenExecutive Officer
- Offering amount
- $50M
- Amount sold
- $50M
- Minimum investment
- $8
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$55.9MraisedAug 2019 · 13 investors · BiotechnologyRule 506(b)
▶$55.9MraisedAug 2019 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Yi LiuExecutive Officer, Director
- Lynn YangDirector
- Carl GordonDirector
- Offering amount
- $56M
- Amount sold
- $55.9M
- Minimum investment
- $2
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Kura OncologyKura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.
KSQ TherapeuticsKSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Companies working in the same space as Kumquat Biosciences.
Frequently asked questions
- What does Kumquat Biosciences do?
- Kumquat Biosciences is a biotech company developing small-molecule cancer therapeutics, combining drug discovery and clinical expertise to advance new oncology treatments. It focuses on translating research into therapies for cancer patients.
- Who founded Kumquat Biosciences?
- Kumquat Biosciences was founded by Yi Liu, Yi Liu, Ph.D. in 2018.
- Who are Kumquat Biosciences's investors?
- Kumquat Biosciences's investors include EcoR1 Capital, OrbiMed, Roche Venture Fund.
- How much funding has Kumquat Biosciences raised?
- Kumquat Biosciences has disclosed $135.9M raised across 3 rounds.
- Where is Kumquat Biosciences headquartered?
- Kumquat Biosciences is headquartered in San Diego, US.